DNA markers to predict chemo response in advanced colon cancer
Part of Cancer, Digestive system clinical trials.
This study uses a blood test to look for specific DNA changes that may help predict how well chemotherapy works in people with metastatic colorectal cancer. The goal is to find markers that could guide future treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have metastatic colorectal cancer that has spread beyond the colon.
- You have already received first-line chemotherapy with FOLFOX or FOLFIRI.
- You have stored blood samples taken before treatment that can be tested.
- Your doctor has documented how your tumor responded to treatment (using scans or progression-free survival).
- Your tumor has been tested for RAS and BRAF gene mutations.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is developing a blood test that looks at DNA signals to see if certain targeted therapies will work for people with metastatic colorectal cancer. It may help doctors choose the right treatment in the future.
This trial checks a blood test for “ctDNA methylation” to see who may be at higher risk of colorectal cancer returning after surgery. It may help doctors better judge whether adjuvant chemotherapy is working or needed.
This trial uses a blood test to track changes in cancer-related DNA markers (methylation) to see how well treatment is working. It is for people with colorectal or small intestinal cancer that has not spread and who have not yet started treatment.
This study tests if checking your blood for tumor DNA after two rounds of chemotherapy can help doctors decide if they can safely lower the dose or switch your treatment. It's for people with advanced colorectal cancer that started on the left side or in the rectum.
This study looks at whether a blood test for tumor DNA (ctDNA) can predict how well immunotherapy works in people with advanced or locally advanced colorectal cancer that has specific genetic features (dMMR/MSI-H). If you qualify, the trial will monitor your ctDNA levels while you receive standard immunotherapy to see if changes in those levels can show early on if the treatment is working.
This study uses a blood test to check for tumor DNA after surgery, which may help doctors decide if you need additional chemotherapy. It is for people with stage 3 colorectal cancer that is removed by surgery.
Hear when a new CRC (Colorectal Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.